Yazar "Bozcuk, Hakan Sat" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Does obesity change the effect of aromatase inhibitors (AIs) on estradiol, leptin, insulin, and IGF-1 serum levels in breast cancer patients?
    (Amer Soc Clinical Oncology, 2012) Artac, Mehmet; Askin, Dudu; Kiyici, Aysel; Eren, Onder Orhan; Oncel, Mufide; Boruban, Melih Cem; Bozcuk, Hakan Sat
    [Abstract Not Availabe]
  • Küçük Resim Yok
    Öğe
    Prognostic significance of adipose tissue distribution and metabolic activity in PET-CT images of patients with metastatic colorectal cancer.
    (Lippincott Williams & Wilkins, 2020) Karacelik, Tuba; Kaya, Bugra; Karaagac, Mustafa; Araz, Murat; Bozcuk, Hakan Sat; Artac, Mehmet
    [Abstract Not Availabe]
  • Küçük Resim Yok
    Öğe
    Prognostic Significance of Adipose Tissue Distribution and Metabolic Activity in PET/CT in Patients with Metastatic Colorectal Cancer
    (Springer, 2023) Karacelik, Tuba; Kaya, Bugra; Korkmaz, Mustafa; Karaagac, Mustafa; Araz, Murat; Eryilmaz, Melek Karakurt; Bozcuk, Hakan Sat
    Purpose In this study, we aimed to evaluate the prognostic significance of adipose tissue distribution and metabolic activity in PET/CT to predict survival in patients with metastatic colorectal cancer (mCRC). Methods The volume, density (HU), and FDG uptake (standardized uptake value (SUV)) of visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) and maximum FDG uptake of the tumor tissue were measured. Subcutaneous adipose tissue of volume-to-density ratio (SAT ratio) was calculated. Results The median OS for the patients with SAT ratio value < -1.1 and >= -1.1 were 38.5 (95% CI 31.54-45.58) and 24.5 (95% CI 14.13-34.93) months, respectively (p = 0.05). During follow-up, 69 patients experienced disease progression. The median progression-free survival (PFS) was 11.03 months (95% CI: 9.11-12.95). Median PFS for patients with tumor SUV max value < 11.5 and >= 11.5 were 9.2 (95% CI 7.25-11.27) and 12.6 (95% CI 10.02-15.27) months, respectively (p = 0.14). Forty-eight patients received bevacizumab therapy. VAT SUV mean (HR: 0.09; 95% CI 0.01-0.52, p = 0.008) was significantly associated with PFS in patients receiving bevacizumab. SAT ratio was the significant parameter for the OS (HR: 0.58; 95% CI 0.33-1.01, p = 0.05) and PFS (HR: 1.99; 95% CI 1.02-3.91, p = 0.043). Conclusions SAT ratio was an independent prognostic factor for survival in patients with mCRC. Higher SAT volume is correlated with longer survival in mCRC patients.